Featured Story

NIH team IDs SARM1 as a key target to neurodegeneration

Investigators at NIH's National Institute of Allergy and Infectious Diseases have come up with new evidence to ID a key culprit involved in the death of neurons and the development of neurodegenerative diseases like Alzheimer's.

Penn team shines a light on blood disorder

Investigators at the Perelman School of Medicine at the University of Pennsylvania. say they have reached some new insights into the structure of a protein complex that is a root cause of a clotting disorder (heparin-induced thrombocytopenia) that strikes patients who receive the anti-clotting drug heparin.

Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance

One of the best known theories as to why people develop Alzheimer's is that toxic clusters of amyloid beta in the brain wipe out memories and trigger dementia in the elderly. Now researchers say that they have determined that the IL1RAP immune pathway could provide a promising avenue for drug developers.

Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's

A study recently published in the Journal of Neuroscience shows a histone deacetylase inhibitor (HDACi)--RGFP966--can rescue the ability to form new memories, a well-known feature to go awry in Alzheimer's disease.

UCSC team reveals key structural component in telomerase enzyme

Scientists at UC Santa Cruz have identified a key structural component of the telomerase enzyme that can contribute to cell proliferation in cancer cells, publishing their findings in Nature Structural and Molecular Biology. And they say that the work could help pave the way to a new, targeted cancer treatment that zeroes in on telomerase.


From Our Sister Sites


Two weeks after Verastem was forced to acknowledge that its lead cancer drug had flopped badly in a clinical study for mesothelioma, founder and Executive Chairman Christoph Westphal has brought out...


Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.